|
WO2019075583A1
|
|
Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
|
|
WO2018157232A1
|
|
Pharmaceutical compositions 'and combinations comprising inhibitors of the androgen receptor a1wd uses thereof
|
|
WO2018094518A1
|
|
Dual mode biophotonic imaging systems and their applications for detection of epithelial dysplasia in vivo
|
|
GB201717718D0
|
|
Compounds
|
|
WO2018045450A1
|
|
Bisphenol a compounds and methods for treating drug-resistant androgen receptor mediated cancers
|
|
WO2017210771A1
|
|
Compounds and compositions for radiation therapy and methods of using the same
|
|
EP3400229A1
|
|
18/19f-labelled compounds which target the prostate specific membrane antigen
|
|
CN108883117A
|
|
The therapeutic agent of metal complex and its nanoparticle formulations based on lipid
|
|
WO2017008165A1
|
|
Classification method and treatment for endometrial cancers
|
|
AU2016263147A1
|
|
Recombinant oncolytic viruses and uses thereof
|
|
CA2929345A1
|
|
Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer
|
|
WO2016141476A1
|
|
Angiotensin receptor blocking drugs for use in cancer treatment
|
|
CA2963289A1
|
|
Apparatus and methods for improving health outcomes of preterm infants
|
|
AU2015266654A1
|
|
Androgen receptor modulators and methods for their use
|
|
CA2944663A1
|
|
Lymphocyte mediated delivery of proteins
|
|
CA2943569A1
|
|
T-cell epitope identification
|
|
US2017196459A1
|
|
Systems for optical imaging of biological tissues
|
|
US2018051340A1
|
|
Methods and uses for diagnosis and treatment of prostate cancer
|
|
US2014342920A1
|
|
Biomarkers for non-hodgkin lymphomas and uses thereof
|
|
KR20170060162A
|
|
Ester derivatives of androgen receptor modulators and methods for their use
|
